Company Analysis
Sign in

Arrowhead Pharmaceuticals, Inc. (ARWR)

Nasdaq: ARWR · Pharmaceutical Preparations · Pasadena, CA · filing with the SEC since 1998
Full chart Alerts Compare
Grade4.7
◀ Past 5.5● Present 4.8▶ Future 4.0
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

134 patents granted to the 6 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Arrowhead Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
134
133 utility, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
9
Against 9 in 2024 and 6 in 2023
Applications published
195
20 of them in 2025
Names they are printed under
6
its own name, a subsidiary, a former name
By yearGrantedApplications published
'10'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals24
Biotechnology12
Organic fine chemistry4
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name6 counted
Arrowhead Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
133 published
Arrowhead Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent
97 granted
14 published
Arrowhead Madison, Inc. a subsidiary
US, as the owner printed on each patent
19 granted
9 published
Arrowhead Research Corporation a former name
US, as the owner printed on each patent
18 granted
7 published
Arrowhead Madison Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
17 published
Arrowhead Research Corporation a former name
named as the applicant on its applications, in US
0 granted
15 published
Names not counted (2)
INTERACTIVE INC
Most of its patents print IT; this name counts in US. 0 granted and 1 published under it are not counted.
INTERACTIVE INC
Most of its patents print IT; this name counts in US. 0 granted and 1 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 23, 202512,503,696RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions thereof, and methods of useBiotechnologyArrowhead Pharmaceuticals, Inc.
Dec 2, 202512,486,502RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of usePharmaceuticalsArrowhead Pharmaceuticals, Inc.
Oct 14, 202512,442,002RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), compositions thereof, and methods of useBiotechnologyArrowhead Pharmaceuticals, Inc.
Oct 14, 202512,441,7565′-cyclo-phosphonate modified nucleotidesOrganic fine chemistryArrowhead Pharmaceuticals, Inc.
Aug 5, 202512,378,558RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of useBiotechnologyArrowhead Pharmaceuticals, Inc.
Jul 22, 202512,365,899RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)PharmaceuticalsArrowhead Pharmaceuticals, Inc.
Jul 22, 202512,365,897RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of usePharmaceuticalsArrowhead Pharmaceuticals, Inc.
Feb 11, 202512,221,610RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of useBiotechnologyArrowhead Pharmaceuticals, Inc.
Jan 7, 202512,188,017Compositions and methods for inhibiting gene expression of alpha-1 antitrypsinPharmaceuticalsArrowhead Pharmaceuticals, Inc.
Dec 24, 202412,173,086Alpha-v beta-6 integrin ligands and uses thereofBiotechnologyArrowhead Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388900Compositions and Methods for Inhibition of Factor XII Gene ExpressionPharmaceuticalsArrowhead Pharmaceuticals, Inc.
Dec 11, 20252025/0376688RNAi Agents for Inhibiting Expression of Proprotein Convertase Subtilisin Kexin 9 (PCSK9), Pharmaceutical Compositions Thereof, and Methods of UsePharmaceuticalsArrowhead Pharmaceuticals, Inc.
Nov 6, 20252025/0340877RNAi Agents for Inhibiting Expression of Complement Component C3 (C3), Pharmaceutical Compositions Thereof, and Methods of UsePharmaceuticalsArrowhead Pharmaceuticals, Inc.
Oct 30, 20252025/0333735RNAi Agents for Inhibiting Expression of Complement Component C3 (C3), Pharmaceutical Compositions Thereof, and Methods of UsePharmaceuticalsArrowhead Pharmaceuticals, Inc.
Oct 2, 20252025/0302980RNAi Agents for Inhibiting Expression of Microtubule Associated Protein Tau (MAPT), Compositions Thereof, and Methods of UsePharmaceuticalsArrowhead Pharmaceuticals, Inc.
Sep 18, 20252025/0289843PROCESS FOR PREPARATION OF TARGETING LIGANDSOrganic fine chemistryArrowhead Pharmaceuticals, Inc.
Sep 11, 20252025/0283089TREATMENT OF A NON-ALCOHOLIC FATTY LIVER DISEASEPharmaceuticalsArrowhead Pharmaceuticals, Inc.
Aug 28, 20252025/0270555ORGANIC COMPOSITIONS TO TREAT BETA-CATENIN-RELATED DISEASESPharmaceuticalsArrowhead Pharmaceuticals, Inc.
Jul 31, 20252025/0243485Targeting Ligands For Therapeutic CompoundsPharmaceuticalsArrowhead Pharmaceuticals, Inc.
Jul 24, 20252025/0235549ANTI-TRANSFERRIN RECEPTOR ANTIBODIES, CONJUGATES THEREOF, AND USES THEREOFPharmaceuticalsArrowhead Pharmaceuticals, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 19 · Biotechnology 4 · Organic fine chemistry 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ARWR · research, not advice